The Natural Estrogenic Compound Diarylheptanoid (D3): In Vitro Mechanisms of Action and in Vivo Uterine Responses via Estrogen Receptor α

Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina, USA.
Environmental Health Perspectives (Impact Factor: 7.98). 04/2013; 121(4):433-9. DOI: 10.1289/ehp.1206122
Source: PubMed


Background: Diarylheptanoid (D3) isolated from the medicinal plant, Curcuma comosa, has estrogenic activity.
Objective: We aimed to elucidate the mechanism(s) of D3 action and compare it with that of 17β-estradiol (E2) using both in vitro and in vivo uterine models.
Methods: We used human uterine (Ishikawa) cells to determine the estrogenic action of D3 on the activation and nuclear translocation of estrogen receptor α (ERα). In addition, we further characterized the uterine response to D3 treatment in vivo.
Results: D3 activated an estrogen responsive element (ERE) luciferase reporter through ERα, and molecular modeling suggested that D3 could be accommodated in the ERα binding pocket. Using modified ERα to assay ligand-dependent nuclear translocation, we observed D3-dependent ERα interaction and translocation. In mouse uteri, early- and late-phase estrogen-regulated gene responses were increased in D3-treated ovariectomized wild-type animals, in a manner similar to that of E2; no response was seen in ERα knockout animals. We observed a divergence in estrogen responses after D3 treatment: D3 induced robust DNA synthesis in uterine epithelial cells, linked to an increase in cell-cycle–related genes; however, no increase in uterine weight was observed 24 hr after treatment. D3 also affected uterine progesterone receptor expression patterns similar to E2. When D3 and E2 were administered together, we observed no additive or antagonistic effects of D3 on E2. Our findings suggest that D3 is a weak estrogenic agonist compound.
Conclusion: D3 is a weakly acting phytoestrogen that mimics the mitogenic responses produced by E2 in an ERα-dependent manner, but it is unable to increase uterine weight or enhance or antagonize the effects of estrogen.

Download full-text


Available from: Kenneth S Korach, Oct 06, 2015
40 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Postmenopausal osteoporosis is one of the most common disorders in women after menopause, which is linked to an estrogen deficiency and characterized by an excessive loss of trabecular bone. Rubus coreanus and Astragalus membranaceus have been used for their various pharmacological properties in Asia as a traditional medicine. The present study evaluated the anti-osteoporotic effects of the optimal combination of R. coreanus and A. membranaceus in 7:3 mixture (RAM) in ovariectomized (OVX) mice by investigating bone biomechanical properties and the serum levels of TNF-α, osteocalcin, RANKL, OPG, and RANK-RANKL signal-related osteoclast differentiation markers. A total of 36 mature female outbred ICR (Institute of cancer research) strain mice (7 weeks) were divided into 6 groups with 7 mice in each group as follows: (1) Sham-operated control mice (Sham) received daily oral phosphate-buffered-saline (PBS) of equal volumes through gavage. (2) OVX mice received a daily oral gavage of PBS (OVX). (3) OVX mice treated daily with 50mg/kg b.w./day of RAM (4) with 100mg/kg b.w./day of RAM or (5) with 200mg/kg b.w./day of RAM via oral gavage. (6) OVX mice received i.p. injections of 17β-estradiol (E2) (0.1mg/kg b.w./day) three times per week for 12wk. Micro-CT images showed that oral administration of RAM to OVX mice prevented tibial bone loss, preserved trabecular bone microarchitecture, and improved bone biomechanical properties. RAM administration also showed recovery effects on the levels of TNF-α, OPG and RANKL concentration in OVX-states. Additionally, we found that the mechanism by which RAM elicited anti-osteoporotic effects was by down-regulating the expression of TRAF6 and NFATc1 in RANKL-RANK pathway, a route of osteoclast differentiation, followed by reducing the production of osteoclast differentiation factors, calcitonin receptors and cathepsin K. Our research strongly suggests that RAM can be clinically used in the prevention and treatment of postmenopausal osteoporosis.
    Journal of ethnopharmacology 12/2013; 151(2). DOI:10.1016/j.jep.2013.12.008 · 3.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Estrogen receptors alpha (ERα) and beta (ERβ) are nuclear transcription factors that are involved in the regulation of many complex physiological processes in humans. Modulation of these receptors by prospective therapeutic agents is currently being considered for prevention and treatment of a wide variety of pathological conditions, such as, cancer, metabolic and cardiovascular diseases, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update of compounds that have been recently reported as modulators of ERs, with a particular focus on their potential clinical applications.
    Steroids 11/2014; 90C. DOI:10.1016/j.steroids.2014.06.012 · 2.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Concerns regarding potential endocrine disrupting chemicals (EDCs) have led to a need for methods to evaluate candidate estrogenic chemicals. Our previous evaluations of two such EDCs revealed a response similar to that of estradiol (E<sub>2</sub>) at 2 hours, but a less robust response at 24 hours, similar to the short-acting estrogen, estriol (E<sub>3</sub>). Microarray analysis using tools to recognize patterns of response have been utilized in the cancer field to develop of biomarker panels of transcripts for diagnosis and selection of treatments most likely to be effective. Biological effects elicited by long vs. short-acting estrogens greatly impact the risks associated with exposures, therefore it is important to develop tools to predict the ability to maintain estrogenic responses. Biological endpoints in uterine tissue and a signature pattern-recognizing tool that identified co-expressed transcripts allowed development and testing of a panel to classify potentially estrogenic compounds using an in vivo system. Although the endpoints are relevant to uterine tissue, the resulting classification of the compounds is important for other sensitive tissues and species. We evaluated biological and transcriptional endpoints with proven short and long-acting estrogens, and verify the use of our approach using a phytoestrogen. With our model, we were able to classify the diarylheptanoid D3 as a short-acting estrogen. We have developed a panel of transcripts as biomarkers which, together with biological endpoints, might be used to screen and evaluate potentially estrogenic chemicals and infer mode of activity.
    Environmental Health Perspectives 01/2015; 123(4). DOI:10.1289/ehp.1307935 · 7.98 Impact Factor
Show more